MX2014012271A - Conjugados bis-polimericos de lipido y peptido y sus nanoparticulas. - Google Patents

Conjugados bis-polimericos de lipido y peptido y sus nanoparticulas.

Info

Publication number
MX2014012271A
MX2014012271A MX2014012271A MX2014012271A MX2014012271A MX 2014012271 A MX2014012271 A MX 2014012271A MX 2014012271 A MX2014012271 A MX 2014012271A MX 2014012271 A MX2014012271 A MX 2014012271A MX 2014012271 A MX2014012271 A MX 2014012271A
Authority
MX
Mexico
Prior art keywords
conjugates
bis
nanoparticles
peptide conjugates
polymer lipid
Prior art date
Application number
MX2014012271A
Other languages
English (en)
Inventor
Ting Xu
He Dong
Jessica Shu
Nikhil Dube
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2014012271A publication Critical patent/MX2014012271A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona conjugados bis-poliméricos de lípido y péptido que contienen un grupo inicial y de bloque hidrófobo que contiene un péptido helicoidal y dos bloques poliméricos. Los conjugados se pueden autoensamblar y formar subunidades de grupos de hélices, que a su vez se autoensamblan y proporcionan nanoportadores micelares para cargas de fármacos y otros agentes. También se revelan las partículas que contienen los conjuntos y los métodos para formar las partículas.
MX2014012271A 2012-04-10 2013-04-10 Conjugados bis-polimericos de lipido y peptido y sus nanoparticulas. MX2014012271A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261622330P 2012-04-10 2012-04-10
US201261668923P 2012-07-06 2012-07-06
PCT/US2013/035924 WO2013155152A1 (en) 2012-04-10 2013-04-10 Bis-polymer lipid-peptide conjugates and nanoparticles thereof

Publications (1)

Publication Number Publication Date
MX2014012271A true MX2014012271A (es) 2015-05-11

Family

ID=49328119

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012271A MX2014012271A (es) 2012-04-10 2013-04-10 Conjugados bis-polimericos de lipido y peptido y sus nanoparticulas.

Country Status (11)

Country Link
EP (1) EP2841083B1 (es)
JP (2) JP6426600B2 (es)
KR (1) KR20140143838A (es)
CN (1) CN104379158A (es)
AU (1) AU2013245989B2 (es)
CA (1) CA2869984C (es)
IL (1) IL235167A0 (es)
IN (1) IN2014DN08781A (es)
MX (1) MX2014012271A (es)
RU (1) RU2014144945A (es)
WO (1) WO2013155152A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9949927B2 (en) 2012-04-10 2018-04-24 The Regents Of The University Of California Bis-polymer lipid-peptide conjugates and nanoparticles thereof
AU2016224760B2 (en) * 2015-02-23 2021-01-28 Nippon Kayaku Kabushiki Kaisha Block copolymer conjugate of physiologically active substance
WO2017059338A1 (en) 2015-10-02 2017-04-06 Cornell University Enzyme-responsive peptide nanofiber compositions and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69940899D1 (de) 1998-05-27 2009-06-25 Genzyme Corp AAV Vektoren zur Herstellung der Medikamente zur konvektion-erhöhten Verabreichung
AU2002325120A1 (en) * 2001-09-10 2003-03-24 Celator Technologies Inc. Unilamellar vesicles stabilized with short chain hydrophilic polymers
WO2009059450A1 (en) * 2007-11-05 2009-05-14 Shanghai Jiaotong University Peptide ligand directed drug delivery
WO2009142892A1 (en) * 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids
EP2414278B1 (en) * 2009-04-03 2019-11-27 University Of Houston Metal nanoparticles functionalized with rationally designed coatings
AU2009356132B2 (en) * 2009-12-03 2015-01-22 Jiangsu Hengrui Medicine Co., Ltd. Liposome of irinotecan or its hydrochloride and preparation method thereof
EP2545072B1 (en) * 2010-03-12 2017-11-22 The Regents of The University of California Lipid-peptide-polymer conjugates and nanoparticles thereof

Also Published As

Publication number Publication date
CN104379158A (zh) 2015-02-25
AU2013245989A1 (en) 2014-10-30
CA2869984A1 (en) 2013-10-17
KR20140143838A (ko) 2014-12-17
EP2841083B1 (en) 2020-08-05
EP2841083A4 (en) 2016-07-13
AU2013245989B2 (en) 2017-03-30
JP6426600B2 (ja) 2018-11-21
JP2018150327A (ja) 2018-09-27
IN2014DN08781A (es) 2015-05-22
RU2014144945A (ru) 2016-05-27
CA2869984C (en) 2021-08-17
EP2841083A1 (en) 2015-03-04
IL235167A0 (en) 2014-12-31
JP2015520126A (ja) 2015-07-16
WO2013155152A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
MX2020000984A (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
HK1212618A1 (zh) 含有非天然氨基酸的藥物遞送綴合物以及其使用方法
PH12015500561A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
HK1206268A1 (en) Non linear multiblock copolymer drug conjugates for the delivery of active agents
EP2844662A4 (en) Novel conjugates with Tetragalnac and PEPTIDE and method for the release of oligonucleotides
IL236472A0 (en) Biodegradable drug delivery for hydrophobic preparations
IN2014DN00101A (es)
EA201290482A1 (ru) Стабильные составы для лиофилизации терапевтических частиц
EP3003281A4 (en) Novel core-shell nanoparticles for oral drug delivery
EP3628335C0 (en) LIPIDNANOPARTICLES FOR DELIVERY OF MRNA TO THE LUNGS
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
NZ709958A (en) Enhanced stability of novel liquid compositions
EP3033113A4 (en) A novel plga-modified polyethylenimine self-assembly nanotechnology for nucleic acid and drug delivery
EP2849770A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE DISPOSAL OF ESSENTIALLY WATER-INSOLICED MEDICINAL PRODUCTS
WO2013028942A8 (en) Targeting microbubbles
MX2015010083A (es) Nanoparticulas biodegradables y clinicamente compatibles como portadores para administracion de farmacos.
EP3065722A4 (en) Nucleic acid nanostructures for in vivo agent delivery
MX2014002062A (es) Nanoparticulas de peptido y usos de las mismas.
WO2012040331A3 (en) Multistage nanoparticles
EP2525835A4 (en) METHODS AND COMPOSITIONS FOR TARGETING CANCER CELL RELEASE USING NANOPARTICLES
MX2014012271A (es) Conjugados bis-polimericos de lipido y peptido y sus nanoparticulas.
MX371297B (es) Una composición farmacéutica que comprende nanopartículas híbridas amorfas estables, de al menos un inhibidor de proteína quinasa y al menos un componente estabilizador polimérico y formador de matriz.
MD4615B1 (ro) Formă solidă izolată de monoclorhidrat de anamorelin, compoziţie farmaceutică şi procedeu de fabricare a formei de dozare farmaceutice care o conţine
WO2014039074A3 (en) Therapeutic compositions and related methods
EP2548594C0 (en) Pharmaceutical dosage forms of intrathecal baclofen and related delivery system